Matched analysis of the prognosis of amelanotic and pigmented melanoma in head and neck. (1st September 2020)

• Record Type: Journal Article
• Authors: Guo, Wei; Yin, Gaofei; Liu, Hongfei; Duan, Hanyuan; Huang, Zhigang; Chen, Xiaohong
• Is Part Of: Acta oto-laryngologica. Volume 140:Number 9(2020)
• Page Start: 777
• Page End: 780
• Publication Date: 2020-09-01
• Subjects: Head and neck mucosal melanoma -- pigmented type -- amelanotic melanoma; Otolaryngology -- Periodicals; Ear -- Diseases -- Periodicals; Throat -- Diseases -- Periodicals; Otolaryngology -- Electronic Resources; Otorhinolaryngologic Diseases; 617.8
• DOI: 10.1080/00016489.2020.1763456
• Languages: English
• ISSNs: 0001-6489

Abstract

Abstract: Background: The prognosis of mucosal melanoma is poor, and the difference in clinical prognosis between patients with and without pigment needs further study. Aim: To analyze data with head and neck mucosal melanoma, and compare the prognosis of patients with and without pigment. Material and methods: The patients of amelanotic melanoma were matched with pigmented type according to age, sex, stage, location of disease, treatment history, tobacco and alcohol history. The Kaplan–Meier and Cox proportional risk regression model was used for analyzation. Results: 46 patients of amelanotic melanoma and 46 of pigmented type were included in this study. The overall survival rate and progression-free survival rate of patients with pigmented melanoma were higher than in patients with amelanotic melanoma (HR = 0.533, p = .035, 95% CI = 0.296–0.957; HR = 0.530, p = .034, 95% CI = 0.294–0.953, respectively), and the risk of distant metastases in patients with amelanotic melanoma was significantly higher than that in patients with pigmented melanoma (HR = 0.474, p = .046, 95% CI = 0.228–0.987). Conclusions and significance: The prognosis and disease-free survival of amelanotic melanoma is worse than for the pigmented type group. More identifying the differences in clinical characteristics will help to further individualized treatment decisions.